CAS Number491-67-8
Synonyms4H-1-BENZOPYRAN-4-ONE,5,6,7-TRIHYDROXY-2-PHENYL; Noroxylin; 5,6,7-TRIHYDROXYFLAVONE; Baicalein; MFCD00017459; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Baicelein; Baicalin
Molecular FormulaC15H10O5
Molecular Weight270.24
Purity98%
Density1.5±0.1 g/cm3
Boiling Point575.9±50.0 °C at 760 mmHg
Melting Point256-271 °C (lit.)
Appearancesolid
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 491-67-8 |
| Catalog No. | 2A-9022229 |
| Chinese Name | 黄芩素； 黄芩苷元 |
| Synonyms | 4H-1-BENZOPYRAN-4-ONE,5,6,7-TRIHYDROXY-2-PHENYL; Noroxylin; 5,6,7-TRIHYDROXYFLAVONE; Baicalein; MFCD00017459; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Baicelein; Baicalin |
| Molecular Formula | C15H10O5 |
| Molecular Weight | 270.24 |
| Purity | 98 |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 575.9±50.0 °C at 760 mmHg |
| Melting Point | 256-271 °C (lit.) |
| Appearance | solid |
| Water Solubility | Soluble in: dimethylformamide |
| Storage Condition | Store sealed at 2-8°C in a ventilated, dry environ |
| Application | Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 mM. |
| HTC | 2932999099 |
| PubChem ID | 24870246 |
| MDL Number | MFCD00017459 |
| SMILES | Oc1cc2OC(=CC(=O)c2c(O)c1O)c3ccccc3 |
| InChI | 1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H |
| InChI Key | FXNFHKRTJBSTCS-UHFFFAOYSA-N |
| Beilstein/REAXYS | 272683 |
| NACRES Code | NA.22 |
| UNSPSC | 12352100 |
| Hazard Symbols | Transport |
| MSDS | msds/22229_1_491_67_8.pdf |
| Bioactivity | Baicalein (5,6,7-Trihydroxyflavone) is a xanthine oxidase inhibitor with an IC50 value of 3.12 mM. Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Xanthine Oxidase Research Areas >> Cancer Natural Products >> Flavonoids Target IC50: 3.12 mM (xanthine oxidase)[1] In Vitro Baicalein suppresses mitogen induced T cell proliferation and cytokine secretion in vitro. Pre-treatment with baicalein significantly suppresses Con A or anti-CD3/CD28 mAb induced proliferation as well as cytokine secretion at 25 μM. Baicalein treatment induces DNA binding of NF-κB but inhibits thioredoxin activity in the nuclear compartment[2]. Baicalein suppresses proliferation, migration, and invasion of MDA-MB-231 cells in a time- and dose-dependent manner. Baicalein significantly decreases the expression of SATB1 in MDA-MB-231 cells. Baicalein also downregulates the expression of Wnt1 and β-catenin proteins and transcription level of Wnt/β-catenin-targeted genes[3]. In Vivo Baicalein suppresses induction of graft versus host disease but does not inhibit homeostatic proliferation of T-cells in mice. This observation clearly shows potent anti-inflammatory activity of baicalein in vivo[2]. Rats treated with baicalein are protected against an increase in heart to body weight ratio, plasma level of brain natriuretic peptides, intraventricular septum thickness, myocardial collagen volume of left ventricle (all P<0.05, respectively). The antifibrotic effects of baicalein are further illustrated by the suppressed expression of left ventricle pro-collagens I and III accompanied by the decreased expression of 12-lipoxygenase, and by reduced expression and activity of matrix metallopeptidase 9 and extracellular signal-regulated kinases. Baicalein can inhibit cardiac fibrosis in hypertensive rats[4]. Cell Assay MTT assay is conducted to evaluate the effect of baicalein on proliferation of breast cancer cells. MDA-MB-231 cells are routinely digested, collected, and then seeded in 96-well plates at a density of 8×103 cells/well. After incubation for 12-24 hours, cells are treated with 0, 20, 40, 60, 80, 100, and 120 μM baicalein according to their experimental grouping and then incubated at 37°C for 24, 48, and 72 hours[3]. Animal Admin Rats: Baicalein is suspended in 1% methylcellulose. Rats are treated with baicalein suspension via oral garvage. SHR and WKY rats are divided into 4 groups (n=8 per group): 12-week treatment with high-dose (200 mg/kg/day) or low-dose (50 mg/kg/day) group; and 4-week treatment with high-dose or low-dose group. The 12-week and 4-week negative control groups of SHR and WKY rats (n=8 per group) receive vehicle while positive control groups (Val group, n=8 per group) receive valsartan (20 mg/kg/day) for comparison[4]. Mice: To study the in vivo anti-inflammatory efficacy of baicalein, graft-versus-host disease (GVHD) model is used. Splenic lymphocytes from C57BL/6 mice are incubated with baicalein in vitro (25 μM, 4h) and adoptively transferred to immune-compromised Balb/c mice[2]. References [1]. Shieh DE,et al. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 2000 Sep-Oct;20(5A):2861-5. [2]. Patwardhan RS, et al. Baicalein exhibits anti-inflammatory effects via inhibition of NF-κB transactivation. Biochem Pharmacol. 2016 May 15;108:75-89. [3]. Ma X, et al. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.Drug Des Devel Ther. 2016 Apr 18;10:1419-41. [4]. Kong EK, et al. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensiverats. Eur J Pharmacol. 2011 May 11;658(2-3):175-81. Chemical & Physical Properties Density 1.5±0.1 g/cm3 Boiling Point 575.9±50.0 °C at 760 mmHg Melting Point 256-271 °C(lit.) Molecular Formula C15H10O5 Molecular Weight 270.237 Flash Point 225.3±23.6 °C Exact Mass 270.052826 PSA 90.90000 LogP 3.31 Vapour Pressure 0.0±1.7 mmHg at 25°C Index of Refraction 1.732 InChIKey FXNFHKRTJBSTCS-UHFFFAOYSA-N SMILES O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12 Storage condition 2-8°C |
| Use of | Properties Articles132 Name baicalein Synonym More Synonyms Baicalein Biological Activity Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Xanthine Oxidase Research Areas >> Cancer Natural Products >> Flavonoids In Vivo Baicalein suppresses induction of graft versus host disease but does not inhibit homeostatic proliferation of T-cells in mice. This observation clearly shows potent anti-inflammatory activity of baicalein in vivo[2]. Rats treated with baicalein are protected against an increase in heart to body weight ratio, plasma level of brain natriuretic peptides, intraventricular septum thickness, myocardial collagen volume of left ventricle (all P<0.05, respectively). The antifibrotic effects of baicalein are further illustrated by the suppressed expression of left ventricle pro-collagens I and III accompanied by the decreased expression of 12-lipoxygenase, and by reduced expression and activity of matrix metallopeptidase 9 and extracellular signal-regulated kinases. Baicalein can inhibit cardiac fibrosis in hypertensive rats[4]. References [1]. Shieh DE,et al. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res. 2000 Sep-Oct;20(5A):2861-5. [2]. Patwardhan RS, et al. Baicalein exhibits anti-inflammatory effects via inhibition of NF-κB transactivation. Biochem Pharmacol. 2016 May 15;108:75-89. [3]. Ma X, et al. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.Drug Des Devel Ther. 2016 Apr 18;10:1419-41. [4]. Kong EK, et al. A novel anti-fibrotic agent, baicalein, for the treatment of myocardial fibrosis in spontaneously hypertensiverats. Eur J Pharmacol. 2011 May 11;658(2-3):175-81. Chemical & Physical Properties Molecular Formula C15H10O5 Exact Mass 270.052826 PSA 90.90000 Index of Refraction 1.732 InChIKey FXNFHKRTJBSTCS-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Botanical Reference Standards | ||
|---|---|---|
| (+)-Bicuculline | 485-49-4 | 2A-9022183 |
| 3-Indoxyl-beta-D-glucopyranoside | 487-60-5 | 2A-9022202 |
| L-Epicatechin | 490-46-0 | 2A-9022218 |
| Quercetin-7-glucoside | 491-50-9 | 2A-9022227 |
| Emodin anthrone | 491-60-1 | 2A-9022228 |
| Luteolin | 491-70-3 | 2A-9022230 |
| Rhapontigenin | 500-65-2 | 2A-9022309 |
| Sennosides | 517-43-1 | 2A-9022444 |
| Emodin | 518-82-1 | 2A-9022455 |
| Physcion | 521-61-9 | 2A-9022482 |
| Browse all Botanical Reference Standards products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS